Latest Conference Coverage

The Interdisciplinary Care Team in Movement Disorder Care: Jean Hubble, MD

The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]

The Importance of Treatment Nuance and Novel Options in Treating Parkinson Disease

In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.

Number and Severity of Cranial Autonomic Symptoms Differ Based on Cluster Headache, Migraine Aura Status

On average, those with cluster headache had 4.8 cranial autonomic symptoms compared with 2.7 for those with migraine, regardless of aura status.

Amantadine Delayed-Release/Extended-Release Capsules Show More Benefit Compared With Other Formulations

In a first, but indirect, comparison of the 3 available formulations of amantadine for the treatment of Parkinson disease, only the delayed-release/extended-release formulation (Gocovri) resulted in improvements in both in OFF time and dyskinesia.

Social Prescribing and Advances in Therapy for Movement Disorders: Jean Hubble, MD

The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]

Opicapone Shows Comparable Efficacy, Safety Among Older Individuals With Parkinson Disease

The investigators noted that the data on tolerability and efficacy support that treatment with opicapone among older adults with PD requires no age-related dose adjustments.

Next Steps in Understanding Patterns of Difficulty Initiating Sleep Among Races, Genders: Afsara Zaheed

The graduate student at the University of Michigan provided insight on the ways to expand the current knowledge about the disparities among races and genders in sleep quality and long-term cognitive outcomes. [WATCH TIME: 3 minutes]

MAGNIMS Score Successfully Predicts Risk of Long-Term of Disability Accumulation

In the comparator study between ponesimod and teriflunomide, the risk of both 12- and 24-week confirmed disability accumulation at week 108 was significantly different between MAGNIMS score groups.

Episode 66: 2022 SLEEP Annual Meeting Highlights

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Afsara Zaheed; Richard Bogan, MD, FCCP, FAASM; and Ruth Benca, MD, PhD. [LISTEN TIME: 18 minutes]

Understanding Treatment Decisions and Differences Between Diroximel Fumarate and Dimethyl Fumarate

Meghan Garabedian, CRNP, MSN, nurse practitioner at the Penn Neuroscience Center, discussed her presentation at the 2022 CMSC Annual Meeting regarding the patient experience on diroximel fumarate.

Improving the Understanding of Narcolepsy and its Pathophysiology: Richard Bogan, MD, FCCP, FAASM

The associate clinical professor at the University of South Carolina School of Medicine discussed the strides, but also challenges still in treating patients with narcolepsy. [WATCH TIME: 2 minutes]

Patient-Reported Outcomes Favor Erenumab Over Topiramate for Migraine in HER-MES Study

Over a 24-week treatment period, 72.2% of those on erenumab achieved relevant improvement on HIT-6 scores compared with 53.9% of those on topiramate.

Feasibility of Incorporating an Interprofessional Student Program to Other Institutions, Universities: Stephanie Teixeira-Poit, PhD

The associate professor at the North Carolina Agricultural and Technical State University provided insight on the widespread feasibility of a new initiative that aims to teach and attract young professionals to the MS field. [WATCH TIME: 4 minutes]

The Importance of Sleep Quality for Cognitive Health Throughout the Stages of Menopause

Dose-Dependent Weight Reductions Observed With Atogepant

In the open-label extension where the highest dose of atogepant (Qulipta; AbbVie) was observed, 24.1% of participants had at least 7% weight loss compared with 14.7% of those on standard of care.

The Effect of Mindfulness Practices on Migraine: Paige Estave, PhD

The MD-PhD student at Wake Forest School of Medicine shared her perspective on the findings of a study suggesting that mindfulness practices can alter pain perception and migraine attack awareness, among other results. [WATCH TIME: 4 minutes]

NeuroVoices: Tanuja Chitnis, MD, on Targeting Anti-CD3, Other Biomarkers in Progressive Multiple Sclerosis

The associate neurologist at Brigham and Women’s Hospital discussed the potential of a nasal anti-CD3 monoclonal antibody, foralumab, and its impact on biomarkers specific to patients with progressive multiple sclerosis.

2022 SMA Research & Clinical Care Meeting: What to Expect

Mary Schroth, MD, and Jacqueline Glascock, PhD, of Cure SMA, share their perspectives on the upcoming annual meeting.

Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms

A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.

Need for Improved Access to and Interventions for Mental Health in Multiple Sclerosis: Louise Palmer, MA

The health research assistant at the Shepherd Center discussed the importance of interventions that address mental health for patients with multiple sclerosis, including counseling and support groups. [WATCH TIME: 2 minutes]

Exposing Young Professionals to Multiple Sclerosis Care, Interdisciplinary Teams: Stephanie Teixeira-Poit, PhD

The associate professor at the North Carolina Agricultural and Technical State University discussed a newfound initiative that helps encourage more professionals in multiple sclerosis and across neurology. [WATCH TIME: 4 minutes]

Investigational DHE Nasal Powder STS101 Shows Tolerability in Phase 3 Study

The most common adverse events reported by individuals using the dihydroergotamine nasal powder were nasal discomfort, dysgeusia, and nasal congestion, all of which were mild and transient in nature.

CGRP Monoclonal Antibodies Show No Significant Impact on Persistent Headaches in Idiopathic Intracranial Hypertension

Secondary outcomes, assessed by the change in the number of monthly headache days by at least 25%, 75%, or 100%, were also not significant following treatment with CGRP monoclonal antibodies.

The Endocannabinoid System and its Relationship to Migraine: Tally Largent-Milnes, PhD

The assistant professor of pharmacology at the University of Arizona College of Medicine Tucson shared her insight into the endocannabinoid system and its therapeutic potential in treating migraine. [WATCH TIME: 5 minutes]

Final Thoughts and Takeaways on MS DMT Discontinuation

Neuronal Complexity in a Model of Migraine: Amynah Pradhan, PhD

The associate professor of psychiatry at the University of Illinois at Chicago shared the findings of her and colleagues’ work that suggest that distinct cytoarchitectural changes occur in the brain that may underlie migraine chronification. [WATCH TIME: 4 minutes]

Women of Reproductive Age Likely Underdiagnosed With Migraine in the ED Setting, Particularly Black and Hispanic Women

Data from a cohort of almost 5000 women seen at Montefiore Health System emergency departments suggest that primary headache, likely migraine, is underdiagnosed, and a high proportion of these women being of Black and Hispanic backgrounds.

Anxiety and Depression in Children and Adolescents With Migraine: Serena L. Orr, MD, MSc

The pediatric neurologist and headache specialist at the University of Calgary discussed the work she presented at AHS 2022 on the incidence of anxiety and depressive disorders in the pediatric migraine population. [WATCH TIME: 6 minutes]

Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence

Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.

The DISCO-MS Study Findings and Clinical Experience